| New strategies for targeting the hypoxic tumour microenvironment in breast cancer C Ward, SP Langdon, P Mullen, AL Harris, DJ Harrison, CT Supuran, ... Cancer treatment reviews 39 (2), 171-179, 2013 | 228 | 2013 |
| Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells F Hochgräfe, L Zhang, SA O'Toole, BC Browne, M Pinese, A Porta Cubas, ... Cancer research 70 (22), 9391-9401, 2010 | 212 | 2010 |
| Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab D Faratian, A Goltsov, G Lebedeva, A Sorokin, S Moodie, P Mullen, C Kay, ... Cancer research 69 (16), 6713-6720, 2009 | 197 | 2009 |
| Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer K Macleod, P Mullen, J Sewell, G Rabiasz, S Lawrie, E Miller, JF Smyth, ... Cancer research 65 (15), 6789-6800, 2005 | 174 | 2005 |
| Regulation of aromatase activity within the breast WR Miller, P Mullen, P Sourdaine, C Watson, JM Dixon, J Telford The Journal of steroid biochemistry and molecular biology 61 (3-6), 193-202, 1997 | 133 | 1997 |
| Novel flavonoids as anti-cancer agents: mechanisms of action and promise for their potential application in breast cancer C Martinez-Perez, C Ward, G Cook, P Mullen, D McPhail, DJ Harrison, ... Biochemical Society Transactions 42 (4), 1017-1023, 2014 | 101 | 2014 |
| Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models C Ward, J Meehan, P Mullen, C Supuran, JM Dixon, JS Thomas, ... Oncotarget 6 (28), 24856, 2015 | 92 | 2015 |
| Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer F McPhillips, P Mullen, BP Monia, AA Ritchie, FA Dorr, JF Smyth, ... British journal of cancer 85 (11), 1753-1758, 2001 | 90 | 2001 |
| Immediate utility of two approved agents to target both the metabolic mevalonate pathway and its restorative feedback loop A Pandyra, PJ Mullen, M Kalkat, R Yu, JT Pong, Z Li, S Trudel, KS Lang, ... Cancer research 74 (17), 4772-4782, 2014 | 85 | 2014 |
| Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines P Mullen, A Ritchie, SP Langdon, WR Miller International journal of cancer 67 (6), 816-820, 1996 | 81 | 1996 |
| PARP cleavage as a means of assessing apoptosis P Mullen Cancer Cell Culture: Methods and Protocols, 171-181, 2004 | 72 | 2004 |
| Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines JY Winum, F Carta, C Ward, P Mullen, D Harrison, SP Langdon, A Cecchi, ... Bioorganic & medicinal chemistry letters 22 (14), 4681-4685, 2012 | 64 | 2012 |
| Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies D Faratian, AJM Zweemer, Y Nagumo, AH Sims, M Muir, M Dodds, ... Clinical Cancer Research 17 (13), 4451-4461, 2011 | 62 | 2011 |
| Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling P Mullen, DA Cameron, M Hasmann, JF Smyth, SP Langdon Molecular cancer therapeutics 6 (1), 93-100, 2007 | 62 | 2007 |
| Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo K Morgan, AJ Stewart, N Miller, P Mullen, M Muir, M Dodds, F Medda, ... Cancer research 68 (15), 6331-6340, 2008 | 58 | 2008 |
| Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells F McPhillips, P Mullen, KG MacLeod, JM Sewell, BP Monia, DA Cameron, ... Carcinogenesis 27 (4), 729-739, 2006 | 58 | 2006 |
| The use of Matrigel to facilitate the establishment of human cancer cell lines as xenografts P Mullen Cancer Cell Culture: Methods and Protocols, 287-292, 2004 | 56 | 2004 |
| Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines KE Wilson, JMS Bartlett, EP Miller, JF Smyth, P Mullen, WR Miller, ... British Journal of Cancer 80 (5), 685-692, 1999 | 55 | 1999 |
| Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy D Faratian, AH Sims, P Mullen, C Kay, IH Um, SP Langdon, DJ Harrison PloS one 6 (8), e23772, 2011 | 54 | 2011 |
| Antitumour activity of the novel flavonoid Oncamex in preclinical breast cancer models C Martínez-Pérez, C Ward, AK Turnbull, P Mullen, G Cook, J Meehan, ... British Journal of Cancer 114 (8), 905-916, 2016 | 53 | 2016 |
David J HarrisonUniversity of St AndrewsVerified email at nucana.com
